Core Viewpoint - The market anticipates a year-over-year decline in earnings for Iridium Communications (IRDM) despite an increase in revenues when it reports its results for the quarter ended December 2025 [1] Earnings Expectations - Iridium is expected to report quarterly earnings of $0.23 per share, reflecting a year-over-year decrease of 25.8% [3] - Revenue projections stand at $219.64 million, which is a 3.1% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 5.26% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Iridium is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.25% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a favorable Zacks Rank [10] - Iridium currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [12] Historical Performance - In the last reported quarter, Iridium exceeded earnings expectations by delivering $0.35 per share against an expected $0.26, resulting in a surprise of +34.62% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Conclusion - While Iridium may not be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [17]

Core Viewpoint - The market anticipates IPG Photonics (IPGP) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for IPG's quarterly earnings is $0.25 per share, reflecting a year-over-year increase of +38.9%. Revenues are projected to be $246.37 million, which is a 5.1% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.71%, indicating a reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +15.08% for IPG, suggesting analysts have become more optimistic about the company's earnings prospects. Additionally, IPG holds a Zacks Rank of 1, indicating a strong likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, IPG exceeded the expected earnings of $0.16 per share by delivering $0.35, resulting in a surprise of +118.75%. Over the past four quarters, the company has beaten consensus EPS estimates three times [12][13]. Conclusion - IPG is positioned as a strong candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [16].

Core Viewpoint - MVB Financial (MVBF) is expected to report a year-over-year decline in earnings due to lower revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The upcoming earnings report is anticipated to show quarterly earnings of $0.31 per share, reflecting a year-over-year decrease of 56.9% [3] - Revenues are projected to be $34.9 million, down 24.4% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not reassessed their initial estimates during this period [4] - MVB Financial's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -14.75%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [9][10] - MVB Financial currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, MVB Financial was expected to post earnings of $0.29 per share but instead reported a loss of -$0.24, resulting in a surprise of -182.76% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Conclusion - MVB Financial does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of its earnings release [17]

Core Viewpoint - The market anticipates Optimum Communications, Inc. (OPTU) to report a year-over-year increase in earnings despite lower revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Company Summary - The expected quarterly loss for Optimum Communications is $0.01 per share, reflecting a significant year-over-year change of +91.7%. Revenues are projected to be $2.15 billion, down 3.9% from the same quarter last year [3]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Optimum Communications is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -100.00%. The company currently holds a Zacks Rank of 5, suggesting a bearish outlook on its earnings prospects [12]. - Historically, Optimum Communications has not beaten consensus EPS estimates in the last four quarters, with the last reported quarter showing a surprise of -200.00% [13][14]. Industry Context - T-Mobile (TMUS), a competitor in the Zacks Wireless National industry, is expected to report an EPS of $2.11 for the same quarter, indicating a year-over-year decline of -17.9%. Its revenues are expected to rise by 8.1% to $23.64 billion [19]. - T-Mobile's consensus EPS estimate has also remained unchanged over the last 30 days, but it has an Earnings ESP of -3.64% and a Zacks Rank of 4, making it difficult to predict an earnings beat [20].

Wall Street expects a year-over-year increase in earnings on higher revenues when PG&E (PCG) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 12, might help the stock move higher if these key numbers are better than expectations. ...

Core Viewpoint - Ingersoll Rand (IR) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results having a significant impact on its near-term stock price [1][2]. Earnings Expectations - The earnings report is expected to be released on February 12, with a consensus EPS estimate of $0.91 per share, reflecting an 8.3% year-over-year increase. Revenues are projected to be $2.05 billion, up 7.8% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.77% over the last 30 days, indicating a reassessment by analysts [4]. However, the Most Accurate Estimate is higher than the consensus, resulting in an Earnings ESP of +0.82%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. Ingersoll currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - Ingersoll has not been able to beat consensus EPS estimates in the last four quarters, with the most recent quarter matching expectations at $0.86 per share, resulting in no surprise [13][14]. Industry Comparison - Watts Water (WTS), another player in the manufacturing sector, is expected to report an EPS of $2.36 for the same quarter, reflecting a 15.1% year-over-year increase, with revenues projected at $611.3 million, up 13.1% [18][19]. Watts Water has a higher Most Accurate Estimate leading to an Earnings ESP of +0.59% and a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating consensus estimates [20].

Core Viewpoint - The market anticipates TransUnion (TRU) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - TransUnion is expected to post quarterly earnings of $1.03 per share, reflecting a year-over-year increase of +6.2% [3]. - Revenues are projected to reach $1.14 billion, marking a 9.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.47% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for TransUnion is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.61%, suggesting a bullish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [9]. Historical Performance - TransUnion has consistently beaten consensus EPS estimates, achieving this in the last four quarters [13]. - In the last reported quarter, TransUnion exceeded expectations by delivering earnings of $1.10 per share against an expected $1.04, resulting in a surprise of +5.77% [12]. Conclusion - TransUnion is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings results when making investment decisions [16].

Core Viewpoint - The market anticipates West Pharmaceutical Services (WST) to report a year-over-year earnings increase driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Group 1: Earnings Expectations - The consensus estimate for quarterly earnings is $1.83 per share, reflecting a year-over-year change of +0.6% [3] - Expected revenues are projected at $794.26 million, which is a 6.1% increase from the same quarter last year [3] Group 2: Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - West Pharmaceutical's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.78%, suggesting a bearish sentiment among analysts [11] Group 3: Historical Performance - In the last reported quarter, West Pharmaceutical exceeded the expected earnings of $1.67 per share by delivering $1.96, resulting in a surprise of +17.37% [12] - The company has beaten consensus EPS estimates in all four of the last quarters [13] Group 4: Market Sentiment and Stock Movement - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - Despite a potential earnings beat, other factors may influence stock performance, making it essential to consider broader market conditions [14][16]

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

Wall Street expects a year-over-year decline in earnings on lower revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...